For the most part, scientists are interpreting the Reversal study to mean that lower is better.
The study tested the same doses of Pravachol and Lipitor that were used in the Reversal study.
If high-dose Lipitor beats Pravachol in Nissen's REVERSAL study, it will encourage doctors to use more powerful cholesterol-lowering options.
The 502-patient Reversal study, conducted by Steven E. Nissen of the Cleveland Clinic, compared the 80-milligram dose of Lipitor to the 40-mg dose of Bristol's Pravachol.
Steven Nissen Steven Nissen, the Cleveland Clinic cardiologist who conducted the Reversal study, saw evidence that even when Pravachol and Lipitor lowered LDL by the same amount, Lipitor seemed to work better.
Given these previous findings in relation to the BDNF pathway following J147 treatment, the effect of J147 on neurotrophic factors was investigated in this AD reversal study.
An interesting result of the reversal study was that aggrecan coating decreased the expression of collagen I back to P0 baseline passage values.
In the reversal studies using PH-797804, serum levels were examined and a significant reduction in serum IL-6 level was seen in the chronic hypoxic and MCT reversal study (Fig. 7, F and G).
The sex-determining locus was mapped to the end of the linkage group 13, in the two mixed sex families from the sex reversal study, using polymorphic Single Nucleotide Polymorphisms (SNP).
Similarly, when administered to ameliorate already existing PH [using a "reversal study" protocol which we previously described (Bertero et al, 2014)] (Fig 5L), anti-miR-210 similarly decreased pulmonary vascular miR-210 (Fig 5M), increased ISCU1/2 expression (Fig 5N), and significantly ameliorated elevations of RVSP and vessel remodeling (Fig 5O– Q).
When intravenously administered to ameliorate already existing PH induced by hypoxia alone without SU5416 ("reversal study"; Fig 6B), endothelial delivery of 7C1-encapsulated anti-miR-210 led to a decrease in miR-210 specifically in PECAM+ pulmonary vascular endothelial cells but not in other PECAM-negative pulmonary cells (Fig 6C).
